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Sllmmary 
The CD40 surface membrane molecule plays an important role in the activation of mature human 
B cells, but its role in earlier stages orB lineage development is unknown. Here, we have investigated 
the effects of triggering the CD40 antigen on B cell precursors (BCP) by crosslinking with anti- 
CD40 antibody presented by Fc'/-receptor type II-transfected murine Ltk- cells (CD40 system). 
CD10 + surface immunoglobulin negative (slg-) BCP, freshly isolated from fetal bone marrow 
or precultured on stromal cells, proliferated in the CD40 system. This effect required the presence 
of IL-3, which acted as a specific cosignal among a panel of cytokines examined. The association 
of IL-10  and  IL-7  potentiated the  observed IL-3  and  CD40-dependent BCP  proliferation, 
demonstrating that IL-10 can act on early B lineage cells. CD40-dependent activation of fetal 
BCP did not favor maturation to slg + B cells, but resulted in the induction of high levels of 
surface membrane CD23.  The emerging CD23 + BCP lacked slg and CD10, and represented 
an important proportion of the cycling cells in the CD40-dependent cultures. Taken together, 
our data demonstrate that stimulation of the CD40 antigen induces expression  of the CD23 
gene, and regulates cell proliferation during normal human B cell ontogeny. 
T 
he life history orB lymphocytes can be divided into two 
major steps. First, an antigen-independent process (B lym- 
phopoiesis) permits constant generation of new immunocom- 
petent surface (s)llgM + slgD + mature B cells in the bone 
marrow (for reviews see references 1 and 2). Then, mature 
B cells can be driven by antigens to proliferate and differen- 
tiate in secondary lymphoid organs (immunopoiesis) (for a 
review see reference 3). Both soluble cytokines and cell mem- 
brane-associated molecules regulate the various  steps of B 
lymphocyte development. In this context, the CD40 B cell 
surface membrane molecule has recently been identified as 
playing a fundamental role in the process of immunopoiesis. 
Human CD40 is a 50-kD glycosylated phosphoprotein (4), 
that belongs to a new superfamily of receptors that includes 
the receptors for nerve growth factor and TNF (5,  6). 
Anti-CD40 antibody presented by Fc',/receptor type II 
(Fc'yRII)  (CDw32)-transfected  murine  fibroblastic  Ltk- 
cells (CD40 system) induces strong and long-lasting B cell 
expansion in the presence of IL-4 (7, 8). The proliferation 
of anti-CD40-activated mature B cells is also enhanced by 
IL-10 (9). More strikingly, IL-10 allows CD40-activated B 
cells to produce large quantities of IgM, IgG, and IgA after 
their  differentiation into  plasma  cells. Culturing  CD40- 
activated naive slgD + slgM + B cells in the presence of IL-4 
or IL-10 and TGF-~ induces the production of IgE or IgA, 
respectively, as a consequence of isotype switching (10-14). 
Recent  studies have  indicated that  CD40  crosslinking 
represents the first step of the interaction between T and B 
cells. A ligand to CD40 has recently been identified and ex- 
pressed from activated T cells, and CD40-Ig fusion proteins 
inhibit T  cell-dependent B cell activation (15--20). 
CD40 is known to be expressed on normal and leukemic 
B cell precursors (BCP), including the earliest B lineage cells 
bearing the progenitor cell antigen CD34 (21-23). However, 
although CD40 triggering has been shown to result in tyro- 
sine phosphorylation of BCP intracellular proteins (24), no 
information is available on the physiological consequences of 
CD40 stimulation in B lymphopoiesis. 
Here, we evaluated the effects of CD40 triggering on BCP 
cultured in the CD40 system. We demonstrate that BCP iso- 
lated from fetal bone marrow can be activated  to undergo 
CD40-dependent proliferation and expression  of CD23. 
1Abbreviations used in this paper: BCP,  B  cell precursor;  BMSC,  bone 
marrow stromal cell; Fc3,RII, Fc'y receptor type II; FSC, forward scatter; 
SCF, stem cell factor; slg,  surface Ig; SSC, side scatter. 
Materials and Methods 
Isolation of BCP.  Mononuclear cells were isolated from mid- 
term human fetal femoral bone marrow by Ficoll-Hypaque, and 
the CD10  § fraction was recovered by panning with anti-CD10 
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Volume 178  July 1993  113-120 mAb  (ALB-1;  Immunotech,  Marseille,  France)  (25).  slg + cells 
were depleted by anti-mouse Ig immunomagnetic beads (Dynabeads 
M450; Dynal, Oslo, Norway) after labeling with a cocktail ofmu- 
fine mAbs directed against  #,/~, ol, y, ic, and X chains (all from 
Immunotech).  The BCP population obtained was  thus  >98% 
CD19 + and lacked  slg (see Fig.  4 A). 
BCP Cultures.  Cultures were performed in Opti-MEM liquid 
medium (Gibco Laboratories,  Grand Island,  NY), supplemented 
with 10% vol/vol heat-inactivated FCS, 10 mM Hepes, 2 mM gluta- 
mine,  5  x  10 -s M  2-~-ME,  penicillin  (100 U/ml),  and strep- 
tomycin (100 #g/ml) (Flow Laboratories,  Irvine, UK). The effects 
of stimulation through the CD40 receptor were either evaluated 
on freshly isolated  fetal CD10 + slg-  BCP (see above),  or after 
preculture of the CD10 § slg- cells on bone marrow stromal cells 
(BMSC) in the presence of 10 ng/ml purified recombinant human 
IIr7 (2.5  ￿  106 U/mg) (R & D Systems, Inc., Minneapolis,  MN). 
The BMSC were isolated from adult human femur material by a 
procedure previously described in detail (26). Coculture of CD10 § 
slg- cells on BMSC results in BCP expansion (26), with obvious 
practical consequences for the present study. 
The CD40 culture system has previously been described (7, 11). 
Freshly isolated or BMSC precultured fetal CD10 § slg- BCP were 
seeded  onto irradiated (7,000  tad)  adherent  murine Ltk-  cells 
transfected with CDw32/FcvRII (CDw32 L cell line), in the pres- 
ence of 500 ng/ml of anti-CD40 mAb (mAb 89) (27) or an isotype- 
matched (IgG1) murine mAb. Cultures in the CD40 system were 
established at a ratio of one CDw32 L cell per two CD10 § sIg- 
BCP. 
Cytokines.  Cell cultures were performed in  the presence of 
purified recombinant human cytokines, at concentrations known 
to be saturating in various biological assays. I1.-3 (sp act, 5  x  104 
U/mg, batch 21294-72-40),  Ib4 (sp act 107 U/mg, batch 8ILE- 
1002),  and  11-10 (sp  act  104 U/mg,  batch  27785-82),  were all 
provided by Schering-Plough Research Institute (Bloomfield, NJ). 
Iblc~ (sp act 108 U/mg), II.,6 (sp act 107 U/mg), stem cell factor 
(SCF)  (sp act 10  s U/mg),  and TNF-o~ (sp act 2  x  107 U/mg), 
were all purchased from Genzyme Corp. (Cambridge, MA). I1,2 
(sp  act 5  x  104 U/rag)  was  obtained from Amgen Biologicals 
(Thousand Oaks,  CA).  IFN-3, (5  x  107 U/mg) was purchased 
from Amersham (Les Ulis, France). Recombinant I1,7 (see above), 
and natural human TGF-18 were from R  & D  Systems,  Inc. 
Proliferation Assays.  For [3H]thymidine incorporation studies, 
BCP  were  seeded  at  104  cells/well  (100  /~1) in  96-well  flat- 
bottomed microtest tissue culture plates (Becton Dickinson & Co., 
Lincoln Park,  NJ), with or without irradiated CDw32 L cells (5 
x  103/well). At time points indicated, cultures were pulsed with 
1/xCi methyl [3H]thymidine (Commissariat  ~ rEnergie Atomique, 
Saclay, France; sp act 25 Ci/mmol) for 8 h, and subsequently har- 
vested. Radioactivity was counted in a H-scintillation  counter, and 
results were expressed as mean cpm  +  SD observed in triplicate 
wells. In parallel,  CD10 + slg- BCP were seeded at 10  s cells/well 
(1 ml) in 24-well tissue culture plates (Nunc, Roskilde, Denmark) 
with or without 5  x  104 irradiated CDw32 L cells. Lymphoid 
cells were subsequently recovered by vigorous pipetting, a proce- 
dure that was sufficient for detachment from the adherent L cells. 
Viable lymphoid cells were subsequently counted in triplicate cul- 
ture wells using a hemocytometer. 
Cytofluorimetric Analysis.  Phenotypic analysis was performed 
using standard surface membrane immunofluorescence technique, 
with FITC-hbeled murine mAbs anti-CD10 and anti-CD19 (Becton 
Dickinson & Co., Mountain View,  CA); anti-CD21  and anti-/~ 
chain (Immunotech); anti-CD23 (28); and anti-CD40 (mAb 89) 
(27). Fluorescence was analyzed on a FACScan  |  (Becton Dickinson 
& Co.), gating out both CDw32 L cells (large size), and nonviable 
lymphoid cells (incorporating propidium iodide). Analysis of  DNA 
content was performed by stoning cells with the DNA-spedfic dye 
Hoechst 33342 (Calbiochem-Novabiocbem, La Jolla, CA) (10 #M, 
for 45 min at 37~  followed by standard surface labeling using 
FITC-conjugated mAbs. Two-color fluorescence was subsequently 
analyzed on a FACStarPlus |  flow cytometer (Becton Dickinson 
& Co.), after excluding CDw32 L cells. 
Results 
Freshly Isolated BCP Proliferate in the CD40 System,  We 
have previously shown  that  mature human B  cells enter a 
state of sustained proliferation when incubated with CDw32/ 
FcyR L cells and anti-CD40 antibody (CD40 system). Here, 
we investigated whether such a system would support  the 
proliferation of purified human BCP.  As illustrated in Fig. 
1, no significant [3H]thymidine uptake was observed when 
highly purified CD10 + slg-  fetal BCP were cultured in the 
presence of anti-CD40 and irradiated CDw32 L cells alone. 
However,  the  addition  of IL-3  to  such  cultures  induced 
[3H]thymidine uptake,  as measured on day 12.  This effect 
was specific for CD40 triggering, as it was not observed upon 
substitution of the anti-CD40 mAb with a control antibody 
(Fig.  1). Addition of soluble anti-CD40 antibody (tested at 
concentrations up to 10/~g/ml) did not stimulate cell prolifer- 
ation, despite the presence of IL-3 (data not shown). Finally, 
as illustrated in Fig.  1, the proliferation of BCP cultured in 
the CD40  system in the presence of IL-3 was  higher than 
in IL-3 alone in  the absence of L  cells. 
BCP cultured in the CD40 system together with IL-3 were 
observed to grow in clumps, in contrast with BCP cultured 
on stromal cell layers. Interestingly, cells grown in the CD40 
system without  IL-3 did not  generate  such clumps. 
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Figure  1.  Freshly  isolated BCP proliferate in the CD40 system. 104 
CD10 + slg- fetal BCP were cultured on 5  x  103 irradiated CDw32 L 
cells with anti-CD40 antibody (mAb 89) or a murine control mAb, with 
or without Ib3. In parallel, the BCP were seeded  without CDw32 L cells, 
with or without II.-3. Data represent mean [3H]thymidine  incorporation 
+_ SD observed  in triplicate  wells on day 12. Anti-CD40 and control mAbs 
were used at 500 ng/ml,  and Ib3 at 10 ng/ml. 
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enhanced proliferation in response to IL-3 after CD40 cross- 
linking. 
BCP Precultured on Stromal Cells Proliferate in  the  CD40 
System.  As human fetal BCP proliferate on BMSC (26, 29), 
we wondered whether such  precuhured cells would also 
proliferate in the CD40  system. Thus, fetal CD10 + slg- 
BCP were expanded for 10 d on BMSC supplemented with 
IL-7,  and 104 precultured cells were seeded onto irradiated 
CDw32 L cells. As illustrated  in Fig.  2 A, no significant 
[3H]thymidine uptake was observed in the absence of anti- 
CD40 mAb. However, addition of IL-3 to stroma-precultured 
BCP resulted in significant levels of [3H]thymidine uptake 
in the CD40 system (Fig. 2 A), whereas IL-1, IL-2, IL-4, 
IL-6, IL-10, SCF, IFN-3,, TNF-c~ and TGF-/3 were inactive 
(Fig. 2 B). The marginal [3H]thymidine uptake observed in 
response to IL-7 (Fig. 2 B) was found to be CD40 independent. 
Whereas IL-1, IL-2, IL-4, IL-6, SCF, IFN-3',  IFN-c~, or 
TGF-B failed to enhance the anti-CD40/IL-3 response of 
stroma-precultured CD10 + slg- BCP (data not shown), the 
association of IL-10 and IL-7 consistently potentiated the in- 
duced DNA synthesis (Fig. 2 A). In some experiments, ad- 
dition of IL-10 or IL-7 alone enhanced the anti-CD40/IL-3 
response, but this effect could not be reproducibly demon- 
strated. 
The DNA synthesis observed in the CD40 system in re- 
sponse to IL-3 plus IL-10 plus IL-7 indeed reflected cell mul- 
tiplication,  as shown by an increase in viable cell numbers 
over a 2-wk culture period (Fig. 3). The CD40 system in 
combination with IL-3 was insuflficient  to expand the overall 
BCP seeded, although higher cell numbers were recovered 
than in the absence oflL-3 (Fig. 3), in line with the observed 
[3H]thymidine data (Figs. 1 and 2).  Finally, BCP did not 
survive beyond 4-5 d on irradiated CDw32 L cells in the 
presence of a control mAb, despite the presence of cytokines 
(data not shown). Taken together, these data demonstrate that 
fetal BCP precuhured on bone marrow stroma proliferate 
specifically  in response to IL-3 after CD40 crosslinking, and 
that this effect is potentiated by IL-7 and IL-10. 
BCP Cultured in the CD40 System Express CD23 and CD21 
but Lose CDIO.  The phenotype of freshly isolated CD10 + 
slg- fetal bone marrow BCP is illustrated in Fig. 4 A. The 
cells displayed CD19,  CD10,  and CD40 antigens, but did 
not express CD21, CD23, or slgM. In addition, freshly iso- 
lated CD10 + slg-  cells display a low 90 ~ light scatter dis- 
tribution (side scatter, SSC) (Fig. 4 A). 
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Figure 2.  Fetal BCP precultured on bone marrow stroma 
proliferate in the CD40 system. (.4) CDIO + slg- BCP were 
expanded 12 d on stromal cells + IL-7,  and subsequently  plated 
(104 cells/well) on 5  x  103 irradiated CDw32 L cells with 
anti-CD40 mAb or a control mAb. Cultures were performed 
in medium alone, in I1,3, in II,3 plus I1,7, in I1,3 plus I1,10, 
or  in  I1,3  plus  I1,7  plus  I1,10. Data  represent  mean 
[3H]thymidine incorporation _+  SD on day 9, as measured 
in triplicate wells. (13) CD10 § slg- BCP were expanded 10 d 
on  stromal  cells plus I1,7,  and subsequently  plated  (104 
cells/well)  in the CD40 system, with various human cytokines: 
I1,1(x, 20 U/ml; I1,2, 20 U/ml; I1,3, 10 ng/ml; I1,4, 50 U/ml; 
I1,6, 20 U/ml; I1,7,  10 ng/ml; I1,10, 100 ng/ml; SCF, 50 
ng/ml; IFN-3,, 500 U/ml; TNF-o~, 50 U/ml; and TGF-3, 
2 ng/ml. Data represent mean [3H]thymidine incorporation 
_+  SD on day 8 of culture,  as measured in triplicate wells. ....  ,  ....  i  ....  n  ....  u 
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tion, also remained slgM- (Fig. 5 F), but a lower propor- 
tion of cells expressed CD23 when compared with cultures 
containing IL-3 alone (15.9% vs 33.2%) (Fig. 5 E). In addi- 
tion, whereas a higher fraction of S + GeM cells was observed 
in the IL-3 plus IL-10 plus IL-7 cultures (15.8%, Fig. 5 D), 
as expected from the proliferation data, the cycling cells ex- 
pressed less CD23 (48.5%  of total S+G2M cells, Fig. 5 E) 
than those cultured with IL-3 alone. 
These results indicate that activation of  BCP through their 
CD40  antigen leads to proliferation  of CD23 + slg-  and 
CD23-  slg-  cells. 
Collectively, our data demonstrate that BCP are induced 
to express CD23 and downregulate CD10 when cultured in 
the CD40 system in the presence of IL-3. 
DAYS 
Figure 3.  Culture of BCP in the CD40 system together with IL-3, II.,7, 
and Ibl0 results in expansion of cell numbers. CD10 + slg- BCP were 
expanded 10 d on stromal cells plus Ib7, and subsequently plated in the 
CD40 system, in medium alone (0), in Ib3 ([]), or in a combination 
of Ib3 plus Ib7 plus Ibl0 (I). Data represent numbers of viable lym- 
phoid cells recovered in triplicate culture wells _+ SD. Ib3 and Ib7 were 
used at  10 ng/ml, whereas I1--10  was added at 100 ng/ml. 
Upon culture in the CD40 system in the presence of IL-3, 
cells segregated into two distinct subsets: R1 with low for- 
ward scatter (FSC) and SSC, and R2 with high FSC and SSC 
(Fig. 4 B). This pattern was dependent upon CD40 triggering, 
as insignificant numbers of R2 cells were found when BCP 
were cultured in  IL-3 in  the presence of a control mAb 
(Fig. 4 C). 
The R1 and R2 cell subsets identified in the CD40 system 
in the presence of IL-3 had substantially different phenotypes, 
although both expressed CD19 and CD21  antigens (Fig. 4 
B).  The R1 population was largely CD10 + and CD23-, 
whereas the R2 population expressed high levels of CD23 
antigen, but no CD10. Furthermore, R.2 cells were slgM- 
(Fig. 4 B), slgD- slgG- (data not shown), whereas the R1 
population  included a significant proportion of slgM + cells 
(Fig. 4 B). 
Induction of CD23 was specific for CD40 triggering, as 
cells in cultures  containing a control mAb were CD23- 
(Fig. 4 C). BCP recovered after preculture of CD10 + slg- 
cells on BMSC were found to exhibit  a similar phenotype 
upon secondary stimulation in the CD40 system (data not 
shown). 
As illustrated in a representative experiment performed on 
stroma-precultured  BCP, 9.3%  of the cells were in cycle 
(S+G2M  phases) after  12  d  of secondary  culture in  the 
CD40 system plus IL-3 (Fig. 5 A). Notably, the cycling calls 
were  mostly included within  the  CD23 +  compartment 
(75.5%  of total S+G2M  calls; Fig. 5 B) and were slgM- 
(Fig. 5 C). The cells also lacked expression of other surface- 
membrane Ig isotypes, and did not display intracytoplasmic 
L chains (data not shown). 
BCP grown in the CD40 system in a combination of IL-3 
plus IL-10 plus IL-7, which resulted in maximal prolifera- 
Discussion 
In the present study, we have demonstrated that human 
BCP proliferate when cultured in the CD40 system in the 
presence of IL-3. However, major differences were observed 
between the responses of BCP and those of mature B cells 
in the CD40 system. First, unlike mature B cells, prolifera- 
tion of BCP appears to be strictly dependent on the presence 
of exogenous cytokines. Interestingly, whereas mature B cell 
proliferation is boosted by IL-4 and to a lesser extent IL-10, 
that of BCP necessitates IL-3 and is further enhanced by ad- 
dition of IL-7 and IL-IO. Notably, IL-4 did not display any 
costimulation effect on BCP cultured in the CD40 system, 
a finding in line with our previous demonstration of the in- 
hibitory effect of IL-4 on BCP proliferation  (30). 
Whereas BCP cultured in the CD40 system in the pres- 
ence of IL-3, IL-7, and IL-10 expanded in number, the mul- 
tiplication rate was much lower than that observed with ma- 
ture B cells in the CD40 system together with IL-4. This 
may reflect the lack of a proliferation  factor important for 
the multiplication  of BCP or a lower proliferative capacity 
of BCP when compared with mature B cells. The latter is 
possible, as committed BCP appear to have a relatively limited 
proliferation potential  in vivo (31), whereas mature B cells 
can expand several  thousand-fold in response to antigen stim- 
ulation,  most particularly  in  germinal centers.  However, 
CDw32 L cells may produce factors inhibiting BCP prolifer- 
ation, which could antagonize the stimulatory effect of CD40 
crosslinking. In line with this notion would be the low re- 
sponsiveness to the combination of IL-7 and IL-3 in the pres- 
ence of CDw32 L cells and control antibody (Fig. 2 A), as 
compared with that of BCP cultured without L cells (25). 
The stimulatory effect of IL-3 on BCP is not dependent 
on CD40 crosslinking, as it has already been reported on BCP 
cultured without antibody or accessory  cells (25, 32). Whereas 
IL-10 has been shown earlier to enhance the proliferation of 
activated mature B lymphocytes (9), it failed to induce the 
proliferation of BCP cultured alone or in the CD40 system. 
Yet, IL-10 was found to enhance the proliferation  of BCP 
cultured in the CD40 system together with IL-3 and IL-7. 
Thus, progenitor B cells represent another cellular target of 
human IL-10. 
Activation of BCP through their CD40 antigen induces 
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Figure  4.  BCP cultured in the CD40 system acquire CD23 antigen.  (A) Light scatter and phenotype of freshly isolated CDI0 + slg-  BCE Dot 
plot illustrates linear forward (FSC, y-axis) vs side (SSC,  x-axis) light scatter. Phenotype histograms represent log of fluorescence (x-axes)  vs relative 
cell numbers using FITC-labeled mAbs. Negative fluorescence control (dotted lines) was provided by a murine mAb of unrelated specificity.  (/3) Light 
scatter and phenotype after culture (day 11) of freshly isolated CD10 + slg- BCP in the CD40 system, with IL-3 (10 ng/ml). Dot plots represent FSC 
vs SSC distribution, which allowed us to identify R1 and R2 cell subsets.  Fluorescence histograms were obtained by gating on the R.1 and R2 popula- 
tions.  (C) Same as (B) except that the BCP were cultured with control mAb instead of anti-CD40 antibody.  Fluorescence histograms correspond to 
the total cell population,  as no  significant R2 subset  was detected. 
the appearance of high SSC cells as analyzed by flow cytom- 
etry. This high SSC population was particularly conspicuous 
when CD40 activation was combined with IL-3, and accord- 
ingly, included the great majority of the proliferating  cells 
in such cultures.  The high SSC population expressed high 
levels of cell surface CD23, a broadly distributed 45-kD gly- 
coprotein (33). CD23 has been described to represent a stage- 
specific marker on slgM + B cells before isotype switching 
in B cell ontogeny (34, 35). The present data, however, dem- 
onstrate that CD23 is inducible before acquisition of slgM. 
In parallel to our results on BCP, it is of interest that mature 
B cells have recently been reported to acquire CD23 upon 
culture in the CD40 system (36). Unlike its effect on mature 
B cells (37),  IL-4 does not appear able to promote CD23 
expression on BCP (35) (our unpublished data). Thus, CD40- 
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mediated induction of CD23 on BCP could be independent 
of IL-4. In this context, the present BCP cultures  are un- 
likely to contain IL-4 which is essentially produced by human 
T cells (38) and basophil/mast cells (39). It will be interesting 
to determine whether the factor inducing CD23 on BCP 
represents a form of the CD40 ligand produced by activated 
T  cells (19). Cycle  analysis indicated  that  most  of the 
S+G2M cells expressed CD23 in the CD40 system in the 
presence of IL-3, but that this proportion was lowered upon 
addition of IL-7 and IL-10 to the cultures. This may be due 
to an inhibitory effect of IL-10 on CD23 expression which 
we have observed on mature B cells (our unpublished data). 
The potential role of CD23 in human B lymphopoiesis re- 
mains to be determined. In this context, the soluble 25-kD 
form of CD23, which is cleaved by autoproteolysis from the +IL-3 ~" 
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Figure  5.  CD40-dependent  activation 
induces  the  proliferation  of  CD23 + 
slgM- and CD23-  slgM- BCP. CD10 + 
slg- BCP were expanded 11 d on stromal 
cells plus IL-7,  and then cultured 12 d in 
the  CD40  system,  with  I1.,3 alone (10 
ng/ml), or with II:3 (10 ng/ml) plus Ib7 
(10 ng/ml) plus IL-10  (100 ng/ml). Data rep- 
resent two-color flow cytometry FACStar  | 
analysis of DNA content (Hoechst 33342) 
vs expression of surface membrane markers. 
Go  +  G, cells (low Hoechst) and S  + 
G2M (high Hoechst), as wall as surface an- 
tigen positive cells, were determined from 
the fluorescence limits indicated on the dot 
plots. Negative surface membrane staining 
was provided by a control mAb of unrelated 
specificity. 
cell surface (40),  displays a broad spectrum of biological ac- 
tivities on hematopoietic cells. Notably, the combination of 
sCD23 and IL-lol induces the development of myeloid pro- 
genitors (41) and the maturation of prothymocytes (42).  It 
will be thus be of interest to determine whether the combi- 
nation of sCD23 and IL-lc~ displays any maturation effects 
on BCP. 
The culture system described herein did not allow the tran- 
sition of BCP into mature B cells even when proliferating 
cells were subsequently transferred into a CD40 system con- 
taining IL-4. In this context, the signal requirement for sIgD 
expression is being actively searched for. It is possible that 
the majority of the BCP triggered in the CD40 system may 
be unable to mature because they are out of phase with the 
developmental stage where CD40 activation occurs in vivo. 
We observed that BCP activated through CD40 down- 
~egulated their CD10 antigen. CD10 is a cell surface metal- 
lopeptidase that has recently been shown to negatively modu- 
late BCP growth (43). Thus, downregulation of CD10 may 
confer a selective advantage in B cell ontogeny. 
Although low levels of CD21 were induced in control cul- 
tures, CD21 expression was considerably enhanced by acti- 
vation in  the CD40  system. Of interest,  CD21  has been 
demonstrated to represent a ligand for CD23  (44),  raising 
the possibility of a CD21-CD23 interaction within our BCP 
cultures. 
The  significance of CD40-mediated  activation of BCP 
deserves further investigation. In view of its well-doctanented 
role on mature B cells, it is tempting to speculate that CD40 
is involved in a selection process at different stages in the life 
history of B lymphocytes. By extension, CD40 may partici- 
pate in a more general network in hematopoiesis. In this con- 
text, we have observed CD40 expression on most CD34 + 
hematopoietic progenitors lacking B lineage markers (23). 
In addition, CD40 may participate in T  cell selection as it 
is expressed on thymic epithelial ceUs (45). 
Since activated T cells express a CD40 ligand, CD40 acti- 
vation may represent a mechanism by which antigen-stimu- 
lated T lymphocytes could regulate hematopoietic develop- 
ment.  Our  present  data demonstrating  that  IL-3  plays  a 
particular role in CD40-dependent BCP proliferation should 
be considered in the context that activated T ceUs represent 
one of the few presently known physiological sources of IL-3. 
Several groups (46-49) have recently established that muta- 
tions in the gene encoding the T ceU CD40 ligand are respon- 
sible for the X-linked HIGM1 hyper-IgM syndrome. As this 
condition  resuhs  in  a  defect in  the  capacity for  isotype 
switching, but not in primary B cell production, it would 
appear that a putative interaction between CD40 and its T 
cell ligand is not an obligate pathway in B cell ontogeny, 
consistent with a mere regulatory function. Alternatively, 
however, the possibility should be considered that CD40 plays 
a more central role in B lymphopoiesis by interacting with 
a second ligand, whose existence has been suggested (50), 
and which could be provided by the BMSC microenviron- 
ment.  In  this respect, it is interesting to note that  other 
members of the CD40 antigen superfamily, such as the TNF 
receptors and the nerve growth factor receptor, bind to sev- 
eral ligands (6). 
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